Related Experiment Video
Updated: Jun 21, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab
1University of Sydney, Discipline of Paediatrics and Child Health, Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, Locked Bag 4001, Westmead, NSW, 2145, Australia. dominif2@chw.edu.au
Insights
Most infants do not need respiratory syncytial virus (RSV) prophylaxis with palivizumab. However, vulnerable infants, like those born extremely preterm or with heart conditions, may benefit from palivizumab to reduce RSV risk.
Area of Science:
- Pediatrics
- Infectious Diseases
- Neonatology
Background:
- Respiratory syncytial virus (RSV) is a common viral infection in infants.
- While most infants experience mild illness, a subset faces severe complications, including intensive care admission and mechanical ventilation.
Purpose of the Study:
- To review strategies for combating RSV infection.
- To evaluate the evidence supporting palivizumab prophylaxis.
- To propose a cost-effective, selective approach to palivizumab use in high-risk infants.
Main Methods:
- Review of existing literature on RSV infection and palivizumab efficacy.
- Analysis of clinical and economic factors influencing palivizumab use.
- Evidence assessment for palivizumab in specific vulnerable infant populations.
Main Results:
- Level II evidence suggests palivizumab can reduce RSV risk by approximately 50% in specific vulnerable infants.
- Palivizumab use varies globally, influenced by economic factors.
- Most infants tolerate RSV infection well and do not require prophylaxis.
Conclusions:
- Palivizumab should be selectively used in the most vulnerable infants during their first six months of life.
- A balanced clinical and economic approach is recommended for palivizumab administration.
- Focusing prophylaxis on high-risk infants optimizes resource allocation and patient outcomes.
Abstract:
As the vast majority of infants tolerate infection with the respiratory syncytial virus [RSV] well and can be managed in the home, most should not be considered for RSV prophylaxis with palivizumab. However, there exists a subset of vulnerable infants in whom the consequences of RSV infection are greater, with an increased likelihood of intensive care admission and mechanical ventilation. These include children born extremely preterm with chronic neonatal lung disease and infants with haemodynamically significant cardiac disease in whom there exists level II evidence to suggest that palivizumab may reduce their risk of acquiring RSV by approximately 50%. The use of palivizumab varies considerably across the world, based largely on economic considerations. This article reviews the strategies developed to fight RSV infection, the evidence for the use of palivizumab and suggests a reasonable approach clinically and economically to the use of palivizumab, proposing its use selectively in the most vulnerable infants during the first six months of life.
More Related Videos
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:30Acute Respiratory Failure-III